The news that Sweden's Isofol Medical AB is planning to go into liquidation and 4D Pharma Plc of the UK has just avoided a similar fate has again demonstrated that biotech in Europe can be a brutal business.
First up, Isofol is to call an extraordinary general meeting (EGM) to discuss paying a cash dividend and liquidating the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?